Company intelligence / Profile preview

Lobe Studio

Vancouver, British Columbia, Canadalobestudio.ca ↗

Ownership: Private
Development stage: Other

Overview

Lobe Sciences has demonstrated first-in-human safety and pharmacokinetics of its proprietary stabilized oral psilocin product (L‑130), showing improved stability and bioavailability over traditional prodrug approaches. The company’s medical food product, Altemia®, generated $1.1M CAD in sales in its first year post-acquisition. Clinical trials are ongoing or planned for chronic cluster headache and addiction.

Therapeutic areas: PsychiatryNeurologyHematology
Modalities: Small moleculeMedical foodPsychedelic-based therapy
Industry: Biotech

Partnerships

Pentec Health (distribution of Altemia)Core One Labs/Vocan Biotechnologies joint venture discussions on biosynthetic psilocybin development/delivery systems

Beyond the preview

Go deeper on Lobe Studio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lobe Studio.

Explore the full profile